RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates interferon (IFN) signallingAs studies in Multiple Myeloma have demonstrated "Reolysin (pelareorep) followed by anti-PD-L1 therapy demonstrated superior efficacy compared to simultaneous co-administration. The pre-treatment with Reolysin is required in order to allow sufficient time for oncolytic reovirus to replicate inside MM cells and subsequently increase PD-L1 expression."
The following study also showed that Reolysin is also able to increase PD-L1 expression in other hematological and solid tumor types that are susceptible to oncolytic reovirus infection and replication and that oncolytic reovirus immune priming is a novel precision approach to selectively induce upregulation of PD-L1 in malignant cells and sensitize cancer cells with low basal PD-L1 expression to anti-PD-1/PD-L1 antibody therapy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844271/